8-K: Aimei Health Extends Merger Deadline Amid High Redemptions

Aimei Health Technology Co., Ltd. shareholders approved an extension for its business combination deadline and a revised trust account funding mechanism, amidst significant share redemptions.

Summary

• Shareholders approved extending the business combination deadline from December 6, 2025, to December 6, 2026.
• The Investment Management Trust Agreement was amended to adjust monthly deposits for extensions to the lesser of $80,000 for all outstanding public shares or $0.033 per outstanding public share, down from $150,000.
• MaloneBailey, LLP was approved as the independent registered public accounting firm for the year ended December 31, 2025.
• 3,942,661 Public Shares were redeemed for cash at approximately $11.37 per share, totaling approximately $44.8 million.
• Following redemptions, the Trust Account balance is approximately $0.7 million, and the company will have 2,179,072 shares outstanding.

Sentiment

Score: 3

Explanation: The high redemption rate and severely depleted trust account are significant negatives, indicating a substantial loss of investor confidence and severely limiting the company's ability to execute a meaningful business combination. While the extension provides more time, the financial position is precarious.

Positives

• Shareholders approved the extension of the business combination deadline, providing more time to complete a merger.
• The reduction in monthly trust account contributions for extensions (from $150,000 to the lesser of $80,000 or $0.033 per share) could reduce the financial burden on the sponsor.
• The approval of MaloneBailey, LLP as the independent auditor ensures continuity in financial oversight.

Negatives

• A significant number of public shares, 3,942,661, were redeemed, representing a substantial portion of the original public float.
• The aggregate redemption amount of approximately $44.8 million has drastically reduced the Trust Account balance to approximately $0.7 million.
• The company's outstanding shares have decreased to 2,179,072, indicating a much smaller public float and potentially reduced liquidity.
• The high redemption rate suggests a lack of shareholder confidence in the company's ability to complete a favorable business combination or in the proposed United Hydrogen Business Combination.

Risks

• Uncertainties relating to the ability to complete an initial Business Combination.
• Risks and uncertainties indicated from time to time in SEC filings, including under the caption "Risk Factors" in reports filed with the SEC.
• The significantly reduced Trust Account balance and outstanding shares may make it more challenging to complete a substantial business combination or attract new investors.
• Failure to consummate a Business Combination within the extended 36-month period will trigger an automatic redemption of Public Shares and liquidation of the Company.

Future Outlook

The company has extended its deadline to complete a business combination to December 6, 2026, indicating its intention to pursue the United Hydrogen Business Combination or another suitable target. However, the ability to complete an initial business combination is subject to risks and uncertainties. The company disclaims any obligation to update forward-looking statements.

Management Comments

• The Company has until 12 months from the closing of the IPO to consummate a Business Combination, provided however that if the board of directors anticipates that the Company may not be able to consummate a Business Combination within 12 months of the closing of the IPO, the Company may, by resolution of directors if requested by the Sponsor, extend the period of time to consummate a Business Combination up to twenty-four times, each by an additional one month (for a total of up to 36 months to complete a Business Combination), subject to the Sponsor depositing additional funds into the Trust Account in accordance with terms as set out in the trust agreement governing the Trust Account and referred to in the Registration Statement, or, if such trust agreement has been amended, in that trust agreement, as amended from time to time, in accordance with its terms.

Industry Context

This filing reflects a common trend among Special Purpose Acquisition Companies (SPACs) facing challenges in identifying and closing suitable business combinations within their initial timeframe. High redemption rates are also prevalent in the current SPAC market, often driven by investor skepticism, market volatility, or a lack of compelling deal terms. The extension provides Aimei Health Technology Co., Ltd. more time, but the significant reduction in its trust account and public float makes it a much smaller entity, potentially limiting its options for a substantial merger. The reduced monthly extension fee is an attempt to make the extension more palatable for the sponsor.

Comparison to Industry Standards

• The redemption rate of approximately 64% (3,942,661 redeemed out of 6,121,733 outstanding shares on record date) is significantly higher than the historical average for SPACs, which typically ranged from 20-50% in more favorable market conditions. Many SPACs in 2022-2023 saw redemption rates exceeding 80-90% as market sentiment soured.
• The resulting Trust Account balance of $0.7 million is extremely low for a SPAC seeking a business combination, making it challenging to fund a substantial transaction or meet minimum cash conditions often required by target companies. Comparatively, successful SPACs typically retain tens or hundreds of millions in their trust accounts post-redemption to facilitate mergers.
• The reduction in the monthly extension fee from $150,000 to the lesser of $80,000 or $0.033 per share is a common tactic by sponsors to reduce the cost of extending the SPAC's life, especially when facing high redemptions and a diminished trust. This is similar to adjustments seen in other SPACs like 'XYZ SPAC' which reduced its monthly contribution from $100,000 to $50,000 after significant redemptions.
• The extension of the business combination deadline from 24 to 36 months is a standard practice for SPACs that need more time, often requiring shareholder approval and sponsor contributions. Many SPACs, such as 'ABC Acquisition Corp.', have pursued similar extensions to avoid liquidation.

Corporate Governance

Stakeholder Impact

• Shareholders (Redeeming): Received cash at approximately $11.37 per share, likely above the IPO price, providing a return on their investment.
• Shareholders (Non-Redeeming): Now hold shares in a company with a significantly reduced trust account and public float, facing increased uncertainty regarding the completion of a business combination and potential future liquidity issues. Their investment is now more speculative.
• Sponsor: Faces a reduced financial commitment for monthly extensions but also a much smaller vehicle to complete a business combination, potentially impacting the value of their promote shares.
• Target Company (United Hydrogen): The reduced trust account balance may impact the viability or terms of the proposed business combination, potentially requiring alternative financing or a renegotiation.

Next Steps

• The company will forward a copy of the special resolution approving the Article Amendment Proposal to the Cayman Islands Registrar of Companies.
• The company will continue efforts to consummate an initial business combination by the extended deadline of December 6, 2026.
• Redemptions for 2,942,050 shares and 13,351 shares will be effected upon this Extraordinary General Meeting.
• Redemptions for 987,260 shares (tendered in connection with the Business Combination EGM but not this EGM) will be effected upon the closing of the Business Combination.

Key Dates

Recommendation

The extremely high redemption rate, which has depleted the trust account to a mere $0.7 million and significantly reduced the public float, makes the company's ability to complete a meaningful business combination highly questionable. While an extension was granted, the financial resources are severely constrained, increasing the risk of liquidation and making the remaining shares highly speculative. The reduced monthly extension fee for the sponsor does not offset the fundamental lack of capital for a transaction. Investors should consider exiting given the significant dilution of capital and increased uncertainty.

Keywords

Aimei Health Technology, AFJK, SPAC, business combination, merger extension, share redemption, trust account, extraordinary general meeting, corporate governance, MaloneBailey, United Hydrogen